Stay updated with breaking news from Nasdaq oric. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) and GH Research (NASDAQ:GHRS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. Volatility and Risk ORIC Pharmaceuticals has a […] ....
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the […] ....
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings estimates for shares of ORIC Pharmaceuticals in a note issued to investors on Monday, February 26th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($1.90) for the year. Cantor Fitzgerald has […] ....
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $10.12, but opened at $10.43. ORIC Pharmaceuticals shares last traded at $10.52, with a volume of 36,713 shares. Analyst Ratings Changes A number of research analysts have weighed in on […] ....
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last […] ....